Nitin Rohatgi, M.D., MBA
Nitin Rohatgi, MD, MBA is a board-certified medical oncologist specializing in breast and genitourinary (GU) cancers, with a strong focus on clinical research and innovation in digital health and artificial intelligence in medicine. He currently practices at Sutter Medical Group/Sutter Medical Center Sacramento, where he has served since 2008 and leads the Breast Cancer Program as Medical Director.
Dr. Rohatgi brings extensive clinical and administrative leadership experience, including serving as Chair of the Section of Hematology/Oncology at Sutter Medical Center Sacramento for over 15 years and leading system-wide oncology initiatives within Sutter Health. His clinical interests center on advancing evidence-based treatments and improving outcomes in breast and GU oncology.
He completed his hematology/oncology fellowship at the University of Cincinnati, where he also served as an Instructor of Clinical Medicine, following residency training in internal medicine at the University of Massachusetts. Dr. Rohatgi earned his MBBS from the All India Institute of Medical Sciences in New Delhi and an MBA with distinction from Heriot-Watt University.
An active member of the American Society of Clinical Oncology, Dr. Rohatgi has authored numerous peer-reviewed publications and presented at national meetings, contributing to advancements in oncology therapeutics and translational research.
Publications
View All Publications from PubMed- Am J Hematol. 2002 Jul;70(3):181-5. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas. Rohatgi N1, LaRocca RV, Bard V, Sethuraman G, Foon KA.Am J Hematol. 2002 Jul;70(3):181-5.2002 Jul 20
- J Womens Health Gend Based Med. 2002 Apr;11(3):291-301.J Womens Health Gend Based Med. 2002 Apr;11(3):291-301.2002 Apr 20
Clinical trials
IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment
Status: Closed to Enrollment
- Clinical trial
Adjuvant Triple NegativeBreast Cancer Ascent-05
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Status: Open to Enrollment
- Clinical trial
Advanced Melanoma Ignyte-3
Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment
Status: Open to Enrollment
- Clinical trial
Advanced Staged Cancer Targeted Therapy ASCO TAPUR
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Status: Open to Enrollment
- Clinical trial
Neoadjuvant Breast Cancer SWOG S2206
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (PM2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
Status: Open to Enrollment